Literature DB >> 9002009

Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls.

S E Gabriel1, C S Crowson, M E Campion, W M O'Fallon.   

Abstract

OBJECTIVE: Compared to rheumatoid arthritis (RA), osteoarthritis (OA) is considered much more benign and much less costly. We sought to describe the economic effects of RA and OA, in terms of the indirect and nonmedical expenditures, compared to nonarthritic controls.
METHODS: Using our unique population based data resources, we developed a model for estimating and comparing disease specific costs among 2 randomly selected, community based samples of 200 patients each with RA and OA and a control group of 200 individuals from the same community who do not have arthritis. Data were collected using a pretested postal survey. Age and sex adjusted comparisons were conducted across the 3 groups, and predictors of cost and utilization were identified using logistic regression modeling.
RESULTS: There were 123, 116, and 94 respondents among the RA, OA, and nonarthritis groups, respectively. The average age and the female-to-male ratios were higher in the OA and RA groups compared to the nonarthritis group. Patients with RA and OA required 3 times more days of care for their conditions compared to nonarthritics (p < 0.0001) and incurred significantly more expenditures for home or child care (p = 0.01) and other services (p = 0.001) (i.e., medical equipment, assistive devices, or home remodeling) compared to nonarthritics. In addition, patients with RA were significantly more likely to have lost their job or to have retired early due to their illness (p = 0.001); were the most likely to have reduced their work hours or stopped working entirely due to their illness (p = 0.003); and were 3 times more likely to have had a reduction in household family income than either individuals with OA or those without arthritis (p = 0.0001). Fifteen percent of respondents with RA were unable to get a job because of their illness, while 3% of respondents with OA and only 1% of nonarthritic respondents reported this experience (p = 0.001). Logistic regression analysis revealed that functional status and pain score, as well as the presence of either RA or OA, were significant predictors of cost and health services utilization.
CONCLUSION: Disease specific indirect and nonmedical costs for OA are substantial and approach those for RA. This has important societal implications, given the high prevalence of OA.

Entities:  

Mesh:

Year:  1997        PMID: 9002009

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  33 in total

Review 1.  Appropriate and effective management of rheumatoid arthritis.

Authors:  F C Breedveld; J R Kalden
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

Review 2.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

Authors:  Marco Barbieri; John B Wong; Michael Drummond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Annual incidence rates of hip symptoms and three hip OA outcomes from a U.S. population-based cohort study: the Johnston County Osteoarthritis Project.

Authors:  A S Moss; L B Murphy; C G Helmick; T A Schwartz; K E Barbour; J B Renner; W Kalsbeek; J M Jordan
Journal:  Osteoarthritis Cartilage       Date:  2016-04-21       Impact factor: 6.576

5.  Sensorimotor changes and functional performance in patients with knee osteoarthritis.

Authors:  M V Hurley; D L Scott; J Rees; D J Newham
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

Review 6.  The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases.

Authors:  Hilal Maradit Kremers; Elena Myasoedova; Cynthia S Crowson; Guergana Savova; Sherine E Gabriel; Eric L Matteson
Journal:  Rheumatology (Oxford)       Date:  2010-07-13       Impact factor: 7.580

7.  Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.

Authors:  Howard G Birnbaum; Crystal Pike; Ritesh Banerjee; Tracy Waldman; Mary Cifaldi
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

8.  Relationship between patient-reported disease severity in osteoarthritis and self-reported pain, function and work productivity.

Authors:  Alesia B Sadosky; Andrew G Bushmakin; Joseph C Cappelleri; David R Lionberger
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

9.  Economic evaluation of a rehabilitation program integrating exercise, self-management, and active coping strategies for chronic knee pain.

Authors:  M V Hurley; N E Walsh; H L Mitchell; T J Pimm; E Williamson; R H Jones; B C Reeves; P A Dieppe; A Patel
Journal:  Arthritis Rheum       Date:  2007-10-15

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.